AFMD - affimed.com Debt to Book Capitalization Ratio

Graphic logo of Affimed N.V. (AFMD)

Strict FDA oversight and antibody patent protection create significant regulatory barriers for Affimed (AFMD). The historical debt-to-market cap ratio visualizes these risks, where 0.00 shows the current value of the metric. Winning the immunotherapy race requires speed in drug delivery, while business resilience depends on having sufficient capital to complete platform testing.

AFMD (Affimed N.V.) Debt to Book Value history from 07/04/2022 to 05/31/2025
Core merchandise of affimed.com

This ratio determines the proportion of borrowed funds within the equity structure, measuring the issuer's financial autonomy. By analyzing the relationship between the company's total debt and book value of equity, an investor distinguishes fundamental stability from market noise. An increase in this metric signals default risks, while a decrease indicates capitalization. For Affimed (AFMD), this balance is critical when financing the environmental modernization of laboratories. Resource optimization requires stable leverage.

Who Affimed competes with

Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ABIVAX (ABVX)|ADMA: Debt to Net Assets Ratio|PTGX (Protagonist Therapeutics Inc) - Debt to Book Capitalization Ratio|Immunovant Therapeutics (IMVT) - Debt to Book Value|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com (GRFS)|Adaptive Biotechnologies Corporation (ADPT) - Debt to Book Value|Debt to Net Assets Ratio Celldex Therapeutics Inc (CLDX)|Debts to Book Capitalization AUPH|BioCryst Corp - Debts to Net Assets|VERA: Debt to Book Capitalization Ratio|DNTH: Debt to Book Value|PHVS (Pharvaris) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|TRML (Tourmaline Corp) - Debt to Book Value|Debts to Book Capitalization PGEN|Debt to Book Capitalization Ratio Pharming Group N.V. PHAR|Debt to Book Value Ratio nektar.com (NKTR)|UPB: Debts to Book Capitalization|Debts to Book Value Zenas Bio ZBIO|Immunome Corp - Debts to Book Capitalization|GOSS - Debts to Book Capitalization|Debts to Book Capitalization KalVista Pharmaceuticals (KALV)|septerna.com (SEPN) - Debts to Book Capitalization Ratio|Debts to Book Capitalization Pieris Pharmaceuticals, Inc. PVLA|Debts to Book Capitalization Ratio Savara Inc|RIGL (Rigel Pharmaceuticals Inc) - Debts to Book Capitalization|Debts to Net Assets ANAB (AnaptysBio Inc.)|Astria Therapeutics - Debt to Book Capitalization Ratio|Debt to Book Value engene.com ENGN|RAPT (RAPT Therapeutics, Inc.) - Debts to Book Capitalization|JBIO - Debts to Book Value|Debts to Book Capitalization Aclaris|Kyverna Therapeutics, Inc (KYTX) - Debt to Book Value Ratio|TLSA (Tiziana Life Sciences) - Debts to Book Capitalization|Debts to Book Capitalization cabalettabio.com|VTYX - Debts to Book Capitalization|Debts to Book Capitalization Ratio THTX (Theratechnologies, Inc.)|Avalo Therapeutics Inc. - Debt to Book Capitalization Ratio|Debt to Book Value Eledon Pharmaceuticals, Inc ELDN|Agenus (AGEN) - Debts to Book Capitalization|CLYM: Debt to Book Value Ratio|Debt to Book Capitalization Ratio Zura Bio Limited (ZURA)|aTyr Pharma Inc (ATYR) - Debts to Book Capitalization Ratio|ADAG - Debts to Book Capitalization|Debt to Net Assets Ratio Ikena Oncology, Inc.|Debts to Book Capitalization STTK|Debts to Book Capitalization EQ (equilliumbio.com)|Debt to Book Capitalization Ratio Connect Biopharma Holdings Limited|Immunic Therapeutics - Debt to Net Assets Ratio|ATRA: Debt to Book Capitalization Ratio|IFRX - Debt to Book Value|XFOR: Debts to Book Capitalization|Debts to Book Capitalization Adicet Bio, Inc.|CELU - Debt to Book Value|Debt to Net Assets Ratio INmune Bio Inc|BRNS (Barinthus Bio) - Debts to Book Capitalization|Debts to Net Assets KZR (Kezar Life Sciences Inc)|SAB Biotherapeutics - Debt to Book Capitalization Ratio|akaritx.com - Debt to Book Value|ENLV: Debt to Book Capitalization Ratio|Q32 Bio Inc. (QTTB) - Debt to Book Value|GOVX: Debt to Book Value|EDSA (Edesa Biotech Corp) - Debts to Book Capitalization|Debt to Book Capitalization Ratio iBio, Inc. (IBIO)|Debt to Book Value Ratio Carisma Tx|XTL Biopharmaceuticals Ltd. - Debts to Book Capitalization|Debts to Book Value boltbio.com (BOLT)|Debts to Book Capitalization HCWB (HCW Biologics)|Debts to Book Capitalization Aptevo Therapeutics, Inc. APVO|Debts to Book Capitalization AIM ImmunoTech|ADTX - Debts to Book Capitalization Ratio|Debts to Book Capitalization GRI Bio (GRI)|XORTX Therapeutics Inc (XRTX) - Debts to Book Capitalization Ratio|HIND: Debts to Book Capitalization|Debts to Net Assets REVB|Debt to Book Capitalization Ratio INDP (Indaptus Therapeutics)|Debt to Book Value scinai.com (SCNI)|CALI: Debts to Book Capitalization|Debts to Book Value Allakos Inc ALLK|HOOKIPA (HOOK) - Debts to Book Capitalization|IGMS - Debt to Book Value Ratio|ITOS: Debts to Book Capitalization|oceanbiomedical.com (OCEA) - Debts to Book Capitalization|Debts to Book Capitalization TC BioPharm TCBP|Debts to Book Capitalization Ratio THRD